CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer

Cell

Volumn 163, Issue 1, 2015, Pages 174-186

  Wang, Yubao ^a,b   Zhang, Tinghu ^a,b   Kwiatkowski, Nicholas ^c   Abraham, Brian J ^c   Lee, Tong Ihn ^c   Xie, Shaozhen ^a,b   Yuzugullu, Haluk ^a,b   Von, Thanh ^a,b   Li, Heyuan ^a   Lin, Ziao ^a   Stover, Daniel G ^a   Lim, Elgene ^a   Wang, Zhigang C ^a,d   Iglehart, J Dirk ^a,d   Young, Richard A ^c,e   Gray, Nathanael S ^a,b   Zhao, Jean J ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 7; THZ 1; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE; CYCLIN-DEPENDENT KINASE-ACTIVATING KINASE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; CRISPR CAS SYSTEM; DRUG HALF LIFE; ENHANCER REGION; ENZYME INHIBITION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; TUMOR GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; TRANSCRIPTION, GENETIC; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84943784340     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2015.08.063     Document Type: Article

References (55)

1. V.G. Abramson, B.D. Lehmann, T.J. Ballinger, and J.A. Pietenpol Subtyping of triple-negative breast cancer: implications for therapy Cancer 121 2015 8 16
2. M.S. Akhtar, M. Heidemann, J.R. Tietjen, D.W. Zhang, R.D. Chapman, D. Eick, and A.Z. Ansari TFIIH kinase places bivalent marks on the carboxy-terminal domain of RNA polymerase II Mol. Cell 34 2009 387 393
3. F. Andre, B. Job, P. Dessen, A. Tordai, S. Michiels, C. Liedtke, C. Richon, K. Yan, B. Wang, G. Vassal, and et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array Clin. Cancer Res. 15 2009 441 451
4. A. Bafico, G. Liu, L. Goldin, V. Harris, and S.A. Aaronson An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells Cancer Cell 6 2004 497 506
5. T.M. Brand, M. Iida, E.F. Dunn, N. Luthar, K.T. Kostopoulos, K.L. Corrigan, M.J. Wleklinski, D. Yang, K.B. Wisinski, R. Salgia, and D.L. Wheeler Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer Mol. Cancer Ther. 13 2014 1356 1368
6. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours Nature 490 2012 61 70
7. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
8. Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers Nature 489 2012 519 525
9. L.A. Carey, H.S. Rugo, P.K. Marcom, E.L. Mayer, F.J. Esteva, C.X. Ma, M.C. Liu, A.M. Storniolo, M.F. Rimawi, A. Forero-Torres, and et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer J. Clin. Oncol. 30 2012 2615 2623
10. B. Chapuy, M.R. McKeown, C.Y. Lin, S. Monti, M.G. Roemer, J. Qi, P.B. Rahl, H.H. Sun, K.T. Yeda, J.G. Doench, and et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma Cancer Cell 24 2013 777 790
11. L. Chin, J.N. Andersen, and P.A. Futreal Cancer genomics: from discovery science to personalized medicine Nat. Med. 17 2011 297 303
12. E. Chipumuro, E. Marco, C.L. Christensen, N. Kwiatkowski, T. Zhang, C.M. Hatheway, B.J. Abraham, B. Sharma, C. Yeung, A. Altabef, and et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer Cell 159 2014 1126 1139
13. C.L. Christensen, N. Kwiatkowski, B.J. Abraham, J. Carretero, F. Al-Shahrour, T. Zhang, E. Chipumuro, G.S. Herter-Sprie, E.A. Akbay, A. Altabef, and et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor Cancer Cell 26 2014 909 922
14. B. Corkery, J. Crown, M. Clynes, and N. O'Donovan Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer Ann. Oncol. 20 2009 862 867
15. M.A. Dawson, R.K. Prinjha, A. Dittmann, G. Giotopoulos, M. Bantscheff, W.I. Chan, S.C. Robson, C.W. Chung, C. Hopf, M.M. Savitski, and et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia Nature 478 2011 529 533
16. J.E. Delmore, G.C. Issa, M.E. Lemieux, P.B. Rahl, J. Shi, H.M. Jacobs, E. Kastritis, T. Gilpatrick, R.M. Paranal, J. Qi, and et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc Cell 146 2011 904 917
17. R. Drapkin, G. Le Roy, H. Cho, S. Akoulitchev, and D. Reinberg Human cyclin-dependent kinase-activating kinase exists in three distinct complexes Proc. Natl. Acad. Sci. USA 93 1996 6488 6493
18. R. Fisher, L. Pusztai, and C. Swanton Cancer heterogeneity: implications for targeted therapeutics Br. J. Cancer 108 2013 479 485
19. C. Gewinner, Z.C. Wang, A. Richardson, J. Teruya-Feldstein, D. Etemadmoghadam, D. Bowtell, J. Barretina, W.M. Lin, L. Rameh, L. Salmena, and et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling Cancer Cell 16 2009 115 125
20. K. Glover-Cutter, S. Larochelle, B. Erickson, C. Zhang, K. Shokat, R.P. Fisher, and D.L. Bentley TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II Mol. Cell. Biol. 29 2009 5455 5464
21. W. Guo, Z. Keckesova, J.L. Donaher, T. Shibue, V. Tischler, F. Reinhardt, S. Itzkovitz, A. Noske, U. Zurrer-Hardi, G. Bell, and et al. Slug and Sox9 cooperatively determine the mammary stem cell state Cell 148 2012 1015 1028
22. D. Hnisz, B.J. Abraham, T.I. Lee, A. Lau, V. Saint-André, A.A. Sigova, H.A. Hoke, and R.A. Young Super-enhancers in the control of cell identity and disease Cell 155 2013 934 947
23. D. Hnisz, J. Schuijers, C.Y. Lin, A.S. Weintraub, B.J. Abraham, T.I. Lee, J.E. Bradner, and R.A. Young Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers Mol. Cell 58 2015 362 370
24. K.A. Hoadley, C. Yau, D.M. Wolf, A.D. Cherniack, D. Tamborero, S. Ng, M.D. Leiserson, B. Niu, M.D. McLellan, V. Uzunangelov, et al. Cancer Genome Atlas Research Network Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin Cell 158 2014 929 944
25. Y.H. Hsu, J. Yao, L.C. Chan, T.J. Wu, J.L. Hsu, Y.F. Fang, Y. Wei, Y. Wu, W.C. Huang, C.L. Liu, and et al. Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer Cancer Res. 74 2014 4822 4835
26. E.I. Kanin, R.T. Kipp, C. Kung, M. Slattery, A. Viale, S. Hahn, K.M. Shokat, and A.Z. Ansari Chemical inhibition of the TFIIH-associated kinase Cdk7/Kin28 does not impair global mRNA synthesis Proc. Natl. Acad. Sci. USA 104 2007 5812 5817
27. J.F. Knight, R. Lesurf, H. Zhao, D. Pinnaduwage, R.R. Davis, S.M. Saleh, D. Zuo, M.A. Naujokas, N. Chughtai, J.I. Herschkowitz, and et al. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer Proc. Natl. Acad. Sci. USA 110 2013 E1301 E1310
28. N. Kwiatkowski, T. Zhang, P.B. Rahl, B.J. Abraham, J. Reddy, S.B. Ficarro, A. Dastur, A. Amzallag, S. Ramaswamy, B. Tesar, and et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor Nature 511 2014 616 620
29. S. Larochelle, K.A. Merrick, M.E. Terret, L. Wohlbold, N.M. Barboza, C. Zhang, K.M. Shokat, P.V. Jallepalli, and R.P. Fisher Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells Mol. Cell 25 2007 839 850
30. S. Larochelle, R. Amat, K. Glover-Cutter, M. Sansó, C. Zhang, J.J. Allen, K.M. Shokat, D.L. Bentley, and R.P. Fisher Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II Nat. Struct. Mol. Biol. 19 2012 1108 1115
31. T.I. Lee, S.E. Johnstone, and R.A. Young Chromatin immunoprecipitation and microarray-based analysis of protein location Nat. Protoc. 1 2006 729 748
32. J. Lovén, H.A. Hoke, C.Y. Lin, A. Lau, D.A. Orlando, C.R. Vakoc, J.E. Bradner, T.I. Lee, and R.A. Young Selective inhibition of tumor oncogenes by disruption of super-enhancers Cell 153 2013 320 334
33. G. Lu, Q. Zhang, Y. Huang, J. Song, R. Tomaino, T. Ehrenberger, E. Lim, W. Liu, R.T. Bronson, M. Bowden, and et al. Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor Cancer Cell 26 2014 222 234
34. J.S. Parker, M. Mullins, M.C. Cheang, S. Leung, D. Voduc, T. Vickery, S. Davies, C. Fauron, X. He, Z. Hu, and et al. Supervised risk predictor of breast cancer based on intrinsic subtypes J. Clin. Oncol. 27 2009 1160 1167
35. C.M. Perou, T. Sørlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, C.A. Rees, J.R. Pollack, D.T. Ross, H. Johnsen, L.A. Akslen, and et al. Molecular portraits of human breast tumours Nature 406 2000 747 752
36. T. Pukrop, F. Klemm, T. Hagemann, D. Gradl, M. Schulz, S. Siemes, L. Trümper, and C. Binder Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines Proc. Natl. Acad. Sci. USA 103 2006 5454 5459
37. M.M. Schachter, and R.P. Fisher The CDK-activating kinase Cdk7: taking yes for an answer Cell Cycle 12 2013 3239 3240
38. C. Scheel, E.N. Eaton, S.H. Li, C.L. Chaffer, F. Reinhardt, K.J. Kah, G. Bell, W. Guo, J. Rubin, A.L. Richardson, and R.A. Weinberg Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast Cell 145 2011 926 940
39. S.P. Shah, A. Roth, R. Goya, A. Oloumi, G. Ha, Y. Zhao, G. Turashvili, J. Ding, K. Tse, G. Haffari, and et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers Nature 486 2012 395 399
40. G.I. Shapiro Cyclin-dependent kinase pathways as targets for cancer treatment J. Clin. Oncol. 24 2006 1770 1783
41. J. Sohn, S. Liu, N. Parinyanitikul, J. Lee, G.N. Hortobagyi, G.B. Mills, N.T. Ueno, and A.M. Gonzalez-Angulo cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer J. Cancer 5 2014 745 753
42. W.L. Tam, H. Lu, J. Buikhuisen, B.S. Soh, E. Lim, F. Reinhardt, Z.J. Wu, J.A. Krall, B. Bierie, W. Guo, and et al. Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells Cancer Cell 24 2013 347 364
43. J.H. Taube, J.I. Herschkowitz, K. Komurov, A.Y. Zhou, S. Gupta, J. Yang, K. Hartwell, T.T. Onder, P.B. Gupta, K.W. Evans, and et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes Proc. Natl. Acad. Sci. USA 107 2010 15449 15454
44. W.W. Tee, S.S. Shen, O. Oksuz, V. Narendra, and D. Reinberg Erk1/2 activity promotes chromatin features and RNAPII phosphorylation at developmental promoters in mouse ESCs Cell 156 2014 678 690
45. H.H. Truong, J. Xiong, V.P. Ghotra, E. Nirmala, L. Haazen, S.E. Le Dévédec, H.E. Balcioʇlu, S. He, B.E. Snaar-Jagalska, E. Vreugdenhil, and et al. β1 integrin inhibition elicits a prometastatic switch through the TGFβ-miR-200-ZEB network in E-cadherin-positive triple-negative breast cancer Sci. Signal. 7 2014 ra15
46. N.T. Ueno, and D. Zhang Targeting EGFR in triple negative breast cancer J. Cancer 2 2011 324 328
47. H. Wang, L. He, F. Ma, M.M. Regan, S.P. Balk, A.L. Richardson, and X. Yuan SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/β-catenin activation in breast cancer J. Biol. Chem. 288 2013 6478 6487
48. T. Watabe, K. Yoshida, M. Shindoh, M. Kaya, K. Fujikawa, H. Sato, M. Seiki, S. Ishii, and K. Fujinaga The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor Int. J. Cancer 77 1998 128 137
49. Z. Weihua, R. Tsan, W.C. Huang, Q. Wu, C.H. Chiu, I.J. Fidler, and M.C. Hung Survival of cancer cells is maintained by EGFR independent of its kinase activity Cancer Cell 13 2008 385 393
50. W.A. Whyte, D.A. Orlando, D. Hnisz, B.J. Abraham, C.Y. Lin, M.H. Kagey, P.B. Rahl, T.I. Lee, and R.A. Young Master transcription factors and mediator establish super-enhancers at key cell identity genes Cell 153 2013 307 319
51. J. Xu, Y. Chen, and O.I. Olopade MYC and Breast Cancer Genes Cancer 1 2010 629 640
52. J. Yang, S.A. Mani, J.L. Donaher, S. Ramaswamy, R.A. Itzykson, C. Come, P. Savagner, I. Gitelman, A. Richardson, and R.A. Weinberg Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis Cell 117 2004 927 939
53. L. Yang, X. Wu, Y. Wang, K. Zhang, J. Wu, Y.C. Yuan, X. Deng, L. Chen, C.C. Kim, S. Lau, and et al. FZD7 has a critical role in cell proliferation in triple negative breast cancer Oncogene 30 2011 4437 4446
54. Q. Zhou, T. Li, and D.H. Price RNA polymerase II elongation control Annu. Rev. Biochem. 81 2012 119 143
55. J. Zuber, J. Shi, E. Wang, A.R. Rappaport, H. Herrmann, E.A. Sison, D. Magoon, J. Qi, K. Blatt, M. Wunderlich, and et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Nature 478 2011 524 528